Nowadays, the guidelines for the treatment of hyperprolactinemia mainly recommend CAB as the treatment of choice to control circulating PRL levels and eventual lactotroph tumour growth, in case of PRL-secreting pituitary tumours [16]. This evidence concerns the gene PRL and pituitary tumor.